Baxter International Inc (BAX): Jose E Almeida , CEO of Baxter International Inc purchased 11,691 shares on May 23, 2016. The Insider buying transaction was reported by the company on May 24, 2016 to the Securities and Exchange Commission. The shares were purchased at $42.75 per share for a total value of $499,790.25 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 4, 2016, John D Forsyth (director) sold 1,887 shares at $44.38 per share price.On Mar 15, 2016, Albert P L Stroucken (director) sold 5,660 shares at $40.33 per share price.Also, On Mar 15, 2016, James R Iii Gavin (director) sold 5,660 shares at $40.34 per share price.On Feb 19, 2016, Peter S Hellman (director) sold 5,660 shares at $38.35 per share price.
Shares of Baxter International Inc (BAX) ended Friday, May 20, 2016 session in red amid volatile trading. The shares closed down -0.24 points or -0.56% at $42.92 with 1,16,81,644 shares getting traded. Post opening the session at $43.35, the shares hit an intraday low of $42.89 and an intraday high of $43.51 and the price vacillated in this range throughout the day. The company has a market cap of $23,703 M and the number of outstanding shares has been calculated to be 55,22,62,740 shares. The 52-week high of Baxter International Inc is $46.95 and the 52-week low is $32.18.
On May 3, 2016, Baxter International Inc announced a cash dividend of $0.1300. The company’s management has announced Jun 1, 2016 as the ex-dividend date and fixed the record date on Jun 3, 2016. The payable date has been fixed on Jul 1, 2016.
Company has been under the radar of several Street Analysts.Baxter International Inc is Reiterated by RBC Capital Mkts to Sector Perform and the brokerage firm has raised the Price Target to $ 47 from a previous price target of $40 .The Rating was issued on Apr 27, 2016.Baxter International Inc is Upgraded by Piper Jaffray to Overweight. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Apr 14, 2016.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.